Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders
نویسندگان
چکیده
منابع مشابه
Vortioxetine versus placebo for treatment of major depressive disorder
Introduction: Major depressive disorder is a common mental condition associated with substantial morbidity and economic burden. Approved by the FDA in September 2013 for treatment of episodes of major depressive disorder, Vortioxetine is one of the newer options available in this important area of therapeutics. Materials and methods: A comprehensive literature search (PubMed, the Cochrane libr...
متن کاملAre subsyndromal symptomatic depression and major depressive disorder distinct disorders?
doi: 10.3969/j.issn.1002-0829.2012.05.006 Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China *correspondence: [email protected] Depressive conditions that do not meet full symptomatic or duration criteria for a major depressive disorder (MDD) are of considerable interest to both clinicians and researchers.[1-4] The fo...
متن کاملVortioxetine: a New Treatment for Major Depressive Disorder.
INTRODUCTION Vortioxetine is a structurally novel medication that has recently been approved for treatment of major depressive disorder (MDD). This medication is a serotonin reuptake inhibitor that also has a number of other potentially relevant effects on serotoninergic receptors, which may differentiate the drug's effects from those of current first-line antidepressants, such as selective ser...
متن کاملA Comparison of Emotional Schemas in Patients with Bipolar Disorders and Major Depressive Disorder in Remission and Nonclinical Population
Objective: Similarities and differences among mood disorders can help psychiatrics in their exact diagnosis and more effective treatments. Therefore, the current research sought to identify differences between patients with bipolar disorder, major depressive disorder, and nonclinical group in emotional schemas. Methods: The present research was a cross-sectional study. The research sample cons...
متن کاملvortioxetine versus placebo for treatment of major depressive disorder
introduction: major depressive disorder is a common mental condition associated with substantial morbidity and economic burden. approved by the fda in september 2013 for treatment of episodes of major depressive disorder, vortioxetine is one of the newer options available in this important area of therapeutics. materials and methods: a comprehensive literature search (pubmed, the cochrane libra...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Affective Disorders
سال: 2018
ISSN: 0165-0327
DOI: 10.1016/j.jad.2017.11.081